Rosenberg F, Bataille R, Poubelle P, Joly R, Blotman F, Sany J, Simon L, Serre H
Rev Rhum Mal Osteoartic. 1979 Dec;46(12):665-71.
On the basis of 110 prostatic osteoses that were histologically proven, constantly painful and demonstrated by X-ray, treated by early estrogenotherapy using very high doses, backed up by a high-dose maintenance estrogenotherapy, the authors study the clinical, radiological, histological and biological profile of this metastatic cancer, as well as the response to treatment. The median actuarial survival time of the patients studied is 18.5 months. No statistically significant prognostic correlation was found. Only patients who are clinically estrogen-sensitive, are suffering from bone metastases without a combined visceral conditions, and have a normal initial rate of alcaline phosphates, tend to have a better prognosis (median actuarial survival 31 months versus 18.5 months for the overall population).
基于110例经组织学证实、持续疼痛且X线显示的前列腺骨病，采用极高剂量早期雌激素疗法治疗，并辅以高剂量维持性雌激素疗法，作者研究了这种转移性癌症的临床、放射学、组织学和生物学特征，以及对治疗的反应。所研究患者的中位精算生存时间为18.5个月。未发现具有统计学意义的预后相关性。只有临床对雌激素敏感、患有骨转移且无合并内脏疾病、初始碱性磷酸酶水平正常的患者，预后往往较好（中位精算生存时间为31个月，而总体人群为18.5个月）。
